ストックスクリーナーアプリを入手
4.36
6.24%
-0.29
プレマーケット:
3.61
-0.75
-17.20%
前日終値:
$4.65
開ける：
$4.58
24時間の取引高:
51,740
Relative Volume:
0.36
時価総額：
$230.48M
収益：
-
当期純損益:
$-66.86M
株価収益率:
-3.6333
EPS:
-1.2
ネットキャッシュフロー:
$-58.82M
1週間 パフォーマンス:
+7.39%
1か月 パフォーマンス:
+28.24%
6か月 パフォーマンス:
-21.58%
1年 パフォーマンス:
+17.20%
1日の値動き範囲:
$4.32
$4.69
1週間の範囲:
$3.86
$5.04
52週間の値動き範囲:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
名前
Design Therapeutics Inc
セクター
電話
858-293-4900
住所
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
4.36 | 230.48M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-05-04 | アップグレード | Goldman | Sell → Neutral |
| 2022-06-10 | 開始されました | Wedbush | Outperform |
| 2022-05-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-19 | 開始されました | Goldman | Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-20 | 開始されました | Piper Sandler | Overweight |
| 2021-04-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Design Therapeutics Inc (DSGN) 最新ニュース
Friedreich's Ataxia Market Growth | Trends, Treatments & - openPR.com
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops - Yahoo Finance
Design Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated' - marketscreener.com
Design Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025 - Nasdaq
Design Therapeutics (DSGN) Reveals Positive Phase 1 Trial Results for DT-168 | DSGN Stock News - GuruFocus
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - The Manila Times
JPMorgan Chase & Co. Buys 48,528 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Geode Capital Management LLC Purchases 3,090 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire
Biotech stocks jump as Makary outlines FDA vision, RBC comments - Baystreet.ca
Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025 - Nasdaq
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - The Manila Times
Design Therapeutics Phase 1 Data Shows Promise for Novel FECD Eye Drop Treatment | DSGN Stock News - Stock Titan
Forget the Correction: 2 Artificial Intelligence Stocks That Are Still Worth Buying Anyway - The Globe and Mail
April 2025's Promising Penny Stocks - simplywall.st
Design Therapeutics names new Chief Medical Officer By Investing.com - Investing.com Canada
Design Therapeutics Names Chris Storgard as Chief Medical Officer - marketscreener.com
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics - Business Wire
Design Therapeutics names new Chief Medical Officer - Investing.com Australia
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Manila Times
Breakthrough: Design Therapeutics Strengthens GeneTAC Pipeline with Elite Drug Development Expert as New CMO - Stock Titan
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors - The Manila Times
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential - PNAS
R. W. Roge & Company Inc. Has $1.23 Million Stake in Microsoft Co. (NASDAQ:MSFT) - Defense World
American Century Companies Inc. Purchases 6,481 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Corebridge Financial Inc. Reduces Stock Position in Couchbase, Inc. (NASDAQ:BASE) - Defense World
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update - The Manila Times
AI Proteins CEO Chris Bahl to Speak at TED Main Stage on Next-Generation Miniprotein Therapeutics - Business Wire
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - BioSpace
Charles Schwab Investment Management Inc. Has $1.63 Million Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
New Clinical Trial Details: Gain's Innovative Parkinson's Treatment Heads to Major Conference - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Bank of New York Mellon Corp Sells 3,777 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
VantAI Launches Neo-1, the First AI Model to Rewire Molecular Interactions by Unifying Structure Prediction and Generation for Therapeutic Design - Yahoo Finance
Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR.com
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High? - MSN
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets - The Manila Times
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why - MSN
ElevateBio taps Amazon’s genAI tools to design CRISPR therapeutics - Yahoo Finance
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Design Therapeutics (DSGN) to Release Earnings on Tuesday - Defense World
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Design Therapeutics provides corporate highlights, anticipated milestones - TipRanks
Design Therapeutics, Inc. SEC 10-K Report - TradingView
Design Therapeutics Initiates Phase 1 Trial for DT-216P2; Reports Progress and Financial Results for 2024 - Nasdaq
Design Therapeutics Inc (DSGN) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):